PDCD1 and neoplasm: Hence, there was no very significant positive correlation between TCR clones and tumor-infiltrating lymphocyte (TIL) density at baseline, suggesting that anti-PD-1 therapy may be effective in treating tumors with low TIL TCR clones [11].